Список литературы

Поставить закладку

Лунякова М.А. et al. Патогенез и возможности терапии анемии у детей с острым лимфобластным лейкозом // Вопросы гематологии, онкологии и иммунопатологии в педиатрии. 2013. Vol. 12, № 2. P. 5–16.
Павлов А.Д., Морщакова Е.Ф., Румянцев А.Г. Эритропоэз, эритропоэтин, железо. М.: ГЭОТАР-Медиа, 2011. 304 p.
Безнощенко А.Г. et al. Эритропоэтин в лечение анемии у детей и подростков с острым лимфобластным лейкозом // Детская онкология. 2008. Vol. 3. P. 11–15.
Dicato M. Anemia in Cancer: Some Pathophysiological Aspects // Oncologist. Alphamed Press, 2003. Vol. 8, № S1. P. 19–21.
Dicato M., Plawny L., Diederich M. Anemia in Cancer // Ann. Oncol. 2010. Vol. 21, № Supp. 7. P. 167–172.
Dallalio G., Law E., Means R.T. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations // Blood. Blood, 2006. Vol. 107, № 7. P. 2702–2704.
Wang W. et al. Inﬂuence of Tumor Necrosis Factor-Alpha and Interferon-Gamma on Erythropoietin Production and Erythropoiesis in Cancer Patients With Anemia // Zhonghua Xue Ye Xue Za Zhi. 2007. Vol. 28, № 10. P. 681–684.
Corazza F. et al. Anemia in Children With Cancer Is Associated With Decreased Erythropoietic Activity and Not With Inadequate Erythropoietin Production // Blood. 1998. Vol. 92, № 5. P. 1793–1798.
Kim M.H. et al. Defective erythropoiesis in bone marrow is a mechanism of anemia in children with cancer. // J. Korean Med. Sci. J Korean Med Sci, 2002. Vol. 17, № 3. P. 337–340.
Kivivuori S.M. et al. Serum transferrin receptor and erythropoiesis in children with newly diagnosed acute lymphoblastic leukemia // Leuk. Res. Leuk Res, 1994. Vol. 18, № 11. P. 823–828.
Hellebostad M. et al. Serum immunoreactive erythropoietin in children with acute leukaemia at various stages of disease — and the effects of treatment // Eur. J. Haematol. Eur J Haematol, 1990. Vol. 44, № 3. P. 159–164.
Dowd M. et al. Serum Erythropoietin Levels in Children With Leukemia // Med. Pediatr. Oncol. Med Pediatr Oncol, 1997. Vol. 28, № 4.
Corazza F.V. Physiopathologic Aspects of Anemia and Thrombocytopenia in Children With Cancers: The Roles of Erythropoietin and Thrombopoietin // Bull Mem Acad R Med Belg. 2008. Vol. 163, № 1–2. P. 152–156.
Лунякова М.А. et al. Уровни сывороточного эритропоэтина при анемиях у детей с острым лимфобластным лейкозом до начала химиотерапии // Онкогематология. 2008. Vol. 4. P. 54–55.
Bhavnani M., Morris Jones P.H., Testa N.G. Children in long-term remission after treatment for acute lymphoblastic leukaemia show persisting haemopoietic injury in clonal and long-term cultures // Br. J. Haematol. Br J Haematol, 1989. Vol. 71, № 1. P. 37–41.
Gardner R.V., Astle C.M., Harrison D.E. Hematopoietic Precursor Cell Exhaustion Is a Cause of Proliferative Defect in Primitive Hematopoietic Stem Cells (PHSC) After Chemotherapy // Exp. Hematol. 1997. Vol. 25. P. 495–501.
Yao M. et al. Quantitative and qualitative alterations of long-term culture- initiating cells in patients with acute leukaemia in complete remission // Br. J. Haematol. Br J Haematol, 1998. Vol. 103, № 1. P. 124–128.
Galotto M. et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients // Exp. Hematol. Exp Hematol, 1999. Vol. 27, № 9. P. 1460–1466.
Verfaillie C.M., Catanzarro P.M., Li W.N. Macrophage inﬂammatory protein 1α, interleukin 3 and diffusible marrow stromal factors maintain human hematopoietic stem cells for at least eight weeks in vitro // J. Exp. Med. Rockefeller University Press, 1994. Vol. 179, № 2. P. 643–649.
Shankar A.G. The Role of Recombinant Erythropoietin in Childhood Cancer // Oncologist. Alphamed Press, 2008. Vol. 13, № 2. P. 157–166.
Michon J. Incidence of anemia in pediatric cancer patients in Europe: Results of a large, international survey // Medical and Pediatric Oncology. Med Pediatr Oncol, 2002. Vol. 39, № 4. P. 448–450.
Becker P.S. et al. Hematopoietic growth factors. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 2.2020. 2020. P. 98.
Ludwig H. et al. Iron metabolism and iron supplementation in cancer patients // Wien. Klin. Wochenschr. Springer-Verlag Wien, 2015. Vol. 127, № 23–24. P. 907–919.
Ruggiero A., Riccardi R. Interventions for anemia in pediatric cancer patients // Medical and Pediatric Oncology. 2002. Vol. 39, № 4. P. 451–454.
Marec-Berard P. et al. Risk model predictive of severe anemia requiring RBC transfusion after chemotherapy in pediatric solid tumor patients // J. Clin. Oncol. J Clin Oncol, 2003. Vol. 21, № 22. P. 4235–4238.
Steiner M.E. et al. Recommendations on RBC transfusion support in children with hematologic and oncologic diagnoses from the pediatric critical care transfusion and anemia expertise initiative // Pediatr. Crit. Care Med. Lippincott Williams and Wilkins, 2018. Vol. 19, № 9. P. S149–S156.
Shah N., Andrews J., Goodnough L.T. Transfusions for anemia in adult and pediatric patients with malignancies // Blood Rev. Churchill Livingstone, 2015. Vol. 29, № 5. P. 291–299.
Румянцев А.Г., Аграненко В.А. Гемотрансфузионная терапия в педиатрии и неонатологии: Руководство для врачей. 2002. 644 p.
Ruccione K.S. et al. Association of projected transfusional iron burden with treatment intensity in childhood cancer survivors // Pediatr. Blood Cancer. Pediatr Blood Cancer, 2012. Vol. 59, № 4. P. 697–702.
Supportive Care in Pediatric Oncology. A Practical Evidence-Based Approach / ed. Feusner J., Hastings C.A., Agrawal A.K. Springer Berlin Heidelberg, 2015. 304 p.
King K.E. et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs // Transfusion. Transfusion, 2004. Vol. 44, № 1. P. 25–29.
Dzik W.H. Leukoreduction of blood components // Current Opinion in Hematology. Curr Opin Hematol, 2002. Vol. 9, № 6. P. 521–526.
Rühl H., Bein G., Sachs U.J.H. Transfusion-Associated Graft-Versus-Host Disease // Transfusion Medicine Reviews. Transfus Med Rev, 2009. Vol. 23, № 1. P. 62–71.
Dwyre D.M., Holland P. V. Transfusion-associated graft-versus-host disease // Vox Sanguinis. Vox Sang, 2008. Vol. 95, № 2. P. 85–93.
Buchanan G.R. Blood transfusions in children with cancer and hematologic disorders: Why, when, and how? // Pediatric Blood and Cancer. Pediatr Blood Cancer, 2005. Vol. 44, № 2. P. 114– 116.
Wong E.C.C. et al. Transfusion management strategies: A survey of practicing pediatric hematology/oncology specialists // Pediatric Blood and Cancer. Pediatr Blood Cancer, 2005. Vol. 44, № 2. P. 119–127.
Национальный стандарт Российской Федерации. Кровь донорская и ее компоненты: Руководство по применению компонентов донорской крови. ГОСТ Р 53470-2009. 2010.
Румянцев А.Г., Морщакова Е.Ф., Павлов А.Д. Эритропоэтин: биологические свойства, возрастная регуляция эритропоэза, клиническое применение. М.: ГЭОТАР-МЕД, 2003. 400 p.
Razzouk B.I. et al. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy // J. Clin. Oncol. J Clin Oncol, 2006. Vol. 24, № 22. P. 3583–3589.
Lunyakova M., Rumyantsev A., Demikhov V. Effect of rHuEPO therapy on long-term survival of anemic children with acute lymphoblastic leukemia, undergoing chemotherapy // Haematologica. 2013. Vol. 98, № 1. P. 705.
Abdelrazik N., Fouda M. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: A randomized case-controlled study // Hematology. Hematology, 2007. Vol. 12, № 6. P. 533–541.
Büyükpamukçu M. et al. Is epoetin alfa a treatment option for chemotherapy-related anemia in children? // Med. Pediatr. Oncol. John Wiley & Sons, Ltd, 2002. Vol. 39, № 4. P. 455–458.
Wagner L.M. et al. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: A randomized controlled trial // J. Clin. Oncol. J Clin Oncol, 2004. Vol. 22, № 10. P. 1886–1893.
Hinds P.S. et al. Hemoglobin Response and Improvements in Quality of Life in Anemic Children With Cancer Receiving Myelosuppressive Chemotherapy // J Support Oncol. 2005. Vol. 3, № Suppl. 4. P. 10–11.
Zachariah M. et al. Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy // Pediatr. Hematol. Oncol. Informa Healthcare, 2014. Vol. 31, № 5. P. 442–447.
Durmaz O., Demirkaya M., Sevinir B. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients // Pediatr. Hematol. Oncol. Pediatr Hematol Oncol, 2011. Vol. 28, № 6. P. 461–468.
Hiradfar A., Banihosseinian M. The Efﬁcacy of Recombinant Human Erythropoietin in Treatment Chemotherapy Induced Anemia in Children Diagnosed With a Solid Cancer // Iran J Ped Hematol Oncol. 2014. Vol. 4, № 4. P. 151–159.
Морщакова Е.Ф. et al. Опыт применения эритропоэтина в детской онкологии и онкогематологии // Вопросы гематологии, онкологии и иммунопатологии в педиатрии. 2008. Vol. 7, № 2. P. 16–20.
Marec-Berard P. et al. 2007 Standards, Options, and Recommendations: Use of erythropoiesis- stimulating agents (ESA: Epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer // Pediatric Blood and Cancer. Pediatr Blood Cancer, 2009. Vol. 53, № 1. P. 7–12.
Feusner J. Guidelines for epo use in children with cancer // Pediatric Blood and Cancer. Pediatr Blood Cancer, 2009. Vol. 53, № 3. P. 308–309.
Gewirtz D.A. et al. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs // Clin. Cancer Res. Clin Cancer Res, 2006. Vol. 12, № 7 I. P. 2232–2238.
Bohlius J. et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update // J. Clin. Oncol. American Society of Clinical Oncology, 2019. Vol. 37, № 15. P. 1336–1351.
Bennett C.L. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia // JAMA - J. Am. Med. Assoc. JAMA, 2008. Vol. 299, № 8. P. 914–924.
Hedley B.D., Allan A.L., Xenocostas A. The role of erythropoietin and erythropoiesis- stimulating agents in tumor progression // Clinical Cancer Research. American Association for Cancer Research, 2011. Vol. 17, № 20. P. 6373–6380.
Kokhaei P. et al. Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies // Clin. Cancer Res. Clin Cancer Res, 2007. Vol. 13, № 12. P. 3536–3544.
Takeshita A. et al. Quantitative expression of erythropoietin receptor (EPO-R) on acute leukaemia cells: Relationships between the amount of EPO-R and CD phenotypes, in vitro proliferative response, the amount of other cytokine receptors and clinical prognosis // Br. J. Haematol. Br J Haematol, 2000. Vol. 108, № 1. P. 55–63.
DEL VECCHIO L., LOCATELLI F. Erythropoietin and iron therapy in patients with renal failure // Transfus. Altern. Transfus. Med. John Wiley & Sons, Ltd, 2010. Vol. 11, № 1. P. 20–29.
(UK) N.C.G.C. Alternatives to blood transfusion for patients having surgery: Oral iron, IV iron and erythropoietin. National Institute for Health and Care Excellence (UK), 2015.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница